# Breast Oncology Program

> **NIH NIH P30** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2024 · $183,261

## Abstract

Breast Oncology Program: Summary/Abstract
The goal of the HDFCCC Breast Oncology (BR) Program is to reduce the risk of breast cancer development,
progression, and mortality using innovative approaches and novel methodologies to reveal the molecular,
cellular, and targetable networks that underlie susceptibility, heterogeneity, and outcome disparities. The
translational nature of the program means that laboratory-based work in the program can be rapidly moved into
clinical trials. The clinical research of the BR Program includes reducing overdiagnosis, over- and under-
treatment, and the burden of cancer therapy through risk assessment to individualize screening and prevention
measures, and through improved tumor classification to tailor treatment. BR research focuses on three areas:
(1) understanding how tumor heterogeneity contributes to metastasis, dormancy, and therapeutic resistance;
(2) developing new therapeutic strategies using innovation in trial design and drug development; and (3) better
characterizing early breast lesions to improve screening, prevention, and health care value.

## Key facts

- **NIH application ID:** 10932190
- **Project number:** 5P30CA082103-25
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** ANDREI GOGA
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $183,261
- **Award type:** 5
- **Project period:** 1999-08-05 → 2028-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10932190

## Citation

> US National Institutes of Health, RePORTER application 10932190, Breast Oncology Program (5P30CA082103-25). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10932190. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*